A phase II, doubleblind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, SUSTIVA, DMP 266) in combination with open-label zidovudine with lamivudine at 36 weeks

Authors
Category Primary study
ConferenceInternational Conference on AIDS
Year 1998
This article has no abstract
Epistemonikos ID: 835761de675297ee719ee184e22cf00735b32ee7
First added on: Sep 26, 2019